http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140046530-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_142d981bd6c180968f769e0da8f620da |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b53978e8e1ef8266fdd92e8885ab5a12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8138950c796038e960712670f8013382 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96051390407f2b7ea7ab3195824ae652 |
| publicationDate | 2014-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140046530-A |
| titleOfInvention | Pharmaceutical composition for preventing or treating myeloproliferative disorders, including histone H3Ｋ9 methyltransferase VIIa |
| abstract | The present invention is pharmaceutically acceptable with any one or two or more substances selected from the group consisting of histone H3K9 methyltransferase G9a protein or fragment thereof, activator thereof, expression regulator thereof and histone H3K9 methyltransferase G9a-encoding gene. It provides a pharmaceutical composition for preventing or treating myeloproliferative disorders comprising a carrier. The histone H3K9 methyltransferase G9a according to the present invention inhibits the transcription of JAK2 and inhibits the transcription of HLA-H3K9 methyltransferase gene, HLA-A, in the differentiation induction therapy using ATRA (all-trans retinoic acid, tretinoin) 60, and can be usefully used in the form of a cell therapy agent or a protein therapeutic agent for the treatment or prevention of a disease associated with JAK2 activity and mutation, specifically, a myeloproliferative disorder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190031751-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104491277-A |
| priorityDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.